This Successful Phase III Cancer Drug comes from Sea Squirts

07/04/2016 - 2 minutes

PharmaMar is closer to have another cancer drug on the market, after the success of phase III trials with Aplidin for Multiple Myeloma.

pharmamar_aplidin_plitidepsin_ema_cancerBased in Madrid, PharmaMar is a Biopharma developing anti-cancer drugs, with an interesting strategy for drug discovery. It researches compounds present in marine organisms and assess if they have any biological action on tumor cells.

This kind of bio-mining is being done in many environments – including deserts. For PharmaMar, it yielded 4 potential candidates so far – one of which (Yondelis) is already on the market for soft tissue sarcomas and ovarian cancer.

Now, the company is preparing to submit a second drug Aplidin (plitidepsin) for market authorization with the EMA, the compound of which was obtained from the Sea squirt Aplidium albicans – a sac-like marine invertebrate.

This submission follows positive results from a phase III trial (ADMYRE), which enrolled 255 patients with relapsed/refractory multiple myeloma.

This content is available exclusively to our paying members.

Our members receive the following benefits:

  • Unlock premium articles
  • Download our industry reports
  • Remove all banner ads
  • Access 1,500+ archived posts
  • Support our independent media
Already a member? Sign in
ADVERTISEMENT
Do you want to remove this advert? Become a member!
ADVERTISEMENT
Do you want to remove this advert? Become a member!

Support Us

Become a Member